

Manufacturers Network

Annual General Meeting 2015



Honorable guests





Satellite Symposium on New Technologies

	- , ,	<u> </u>
Day 1, 05 th October 2015	14h00	Satellite Symposium on New Technologies
Dr Priyabrata Pattnaik	Merck- Millipore	Director – Worldwide Vaccine Initiative Merck Millipore (a division of Merck KGaA) Singapore. Dr. Priyabrata Pattnaik is Director of Worldwide Vaccine Initiative of Merck Millipore. He is the global technical/market lead for vaccine initiative supporting R&D and integrated solutions for vaccines and a thought leader on vaccine technology. He was head of Bio-manufacturing Sciences and Training Centre in Singapore and led a group of process engineers providing consulting services, educational seminars and applications support on Merck Millipore's Process Solutions, products and technologies.
Michael Rush	Temptime Corporation	Michael Rush is currently the Executive Director of Global Health Policy for Temptime Corporation, responsible for developing policies in the goal of improving patient health. Prior to Temptime, Mike worked 13 years for Merck Vaccines, he played a major role in in vaccine public sector access, funding and policies in the Americas, while collaborating with CDC, HHS and PAHO. He holds a BA in Industrial Psychology and a MBA in International Business Administration.
Dr Ted Prusik	Temptime Corporation, USA	Dr. Prusik is the Senior Vice President and one of the Founders of Temptime Corporation, manufacturer of the vaccine vial monitor (VVM). He received his BSc degree in Chemistry from Bucknell University and his MSc and PhD degrees in Chemical Physics from NYU. He joined E.R. Squibb and Sons as research investigator in physical chemistry in 1977 then moved to Allied Corporation in 1981. In 1987, the group was spun off as an independent company.
Dr Guenter Jagschies	GE Health Care, European HQ Sweden	Günter Jagschies is Senior Director with GE Healthcare Life Sciences with the BioProcess Division. His current role is Strategic Customer Relations, working globally with industrial R&D collaborations and as an advisor for the GE Healthcare BioProcess R&D and Business team. He holds a PhD in Biochemistry from

the University of Münster, Germany.



	lual G	eneral Meeting 2015
Day 1, 05 th October 2015	17h00	Opening Session
Mahendra Suhardono	PT Bio Farma, Indonesia	Marketing director of Bio Farma. Mr. Suhardono joined Bio Farma in 1989 and occupied various positions including Senior Management and Production Directorate. Major successes include the development and licensing of pentavalent (DTP-HB-Hib) vaccine, preparation of pandemic influenza vaccine and was team leader for ISO 9001, ISO 14001 & OHSAS 18001. Nominated President of DCVMN in 2012 after serving on the executive committee since 2010.
Prof. Sumana Khomvilai	Queen Saovabha Memorial Institute (QSMI) Organizing Committee	Deputy Director of QSMI Organizing Committee. The QSMI founded in 1922 with the mission of manufacturing poisonous snake antisera, rabies immunoglobulins (since 1923), vaccines against tuberculosis (BCG vaccine started in 1953) and other vaccines. Prof.Dr. Sumana is a pharmacist with the experience in pharmaceutical technology and chemistry. She joined QSMI in 1998 and responsible in administrative and management policy of QSMI strategic direction in new processing technology, collaboration of QSMI with government, educational institutes and research center.
Dr. Jean-Marie Okwo-Bele	WHO	Dr Okwo-Bele is the Director of the Department of Immunization, Vaccines and Biologicals (IVB) in the WHO Headquarters in Geneva since August 2004. In this position, he has the responsibility for strategic direction, coordination and management of the WHO normative and programmatic immunization activities, ranging from vaccine research, vaccine quality and safety to immunization policy and immunization services delivery. He oversees a team of nearly 110 IVB professionals in Geneva and collaborates with the WHO network of dedicated vaccines & immunization teams based in 6 regions and 67 countries.
Amie Batson	PATH	Amie Batson, MBA, is responsible for guiding PATH's strategy, strengthening our partnerships and business relationships in the global health community, and contributing to our advocacy and policy priorities. Ms. Batson's 20-year career in global health includes positions with the World Health Organization, the World Bank, UNICEF, and most recently, the US Agency for International Development (USAID), where she served as senior deputy assistant administrator for global health.



Developing Countries Vaccine Manufacturers Network Annual General Meeting 2015

Day 2, 06th october 2015	08h30	Inaugural Session
Vitoon Vonghangool	BioNet- Asia	Mr. Vitoon Vonghangool, President of BioNet Asia Co., Ltd. With 40 years of experience and expertise in marketing vaccines, Mr. Vitoon is the co-founder and President of BioNet-Asia. For years, he has been encouraging vaccine manufacturers within Asia to co-operate on selfsufficiency. Mr. Vitoon started his career with the Rhone—Poulenc Group in 1971. He has created several vaccine ventures and is also an advisor to various biotech organizations. He is a strong advocate for the local development of innovative vaccines in Thailand.
Li Meng	CNBG	Li Meng is the Director of International Cooperation at CNBG, China's largest state-owned biological company and the first WHO-prequalified Chinese vaccine manufacturer. She is currently responsible for managing and executing major international cooperation projects, including projects with NGOs, Multinational partners and research organizations. Her experience in vaccine prequalification, commercialization and cooperative research activities have given her insights in the global vaccine industry. She is also an experienced manager in fund raising, strategy and business development.
Phan Wannamethee	Thai Red Cross	Phan Wannamethee has been Secretary General of the Thai red Cross Society since 1991. Before joining Thai Red Cross, Mr Wannamethee had substantial experience working for the Foreign Ministry of Thailand, as attaché in Washington DC, South of Vietnam and London, and as ambassador in London and Bonn. Mr Wannamethee is an alumnus of Oberlin College Ohio, and obtained his master's degree in International Relations from University of California at Berkley, and also attended National Defence College in Bangkok.
Prof. Visith Sitprija	Queen Saovabha Memorial Institute Organizing Committee	Prof. Visith is Director of QSMI and the WHO Collaborating Centre for Research on Rabies Pathogenesis and Prevention. Emeritus Professor of Medicine of Chulalongkorn University, Prof. Visith began his career as a nephrologist with interest in tropical diseases. His pioneering scientific and clinical work in tropical nephrology earns him national and international recognition. His scientific interest in tropical diseases, natural toxins and



Vitoon Vonghangool



BioNet- Asia

dedication form an important asset for the work of Queen Saovabha Memorial Institute.

Mr. Vitoon Vonghangool, President of BioNet Asia Co., Ltd. With 40 years of experience and expertise in marketing vaccines, Mr. Vitoon is the co-founder and President of BioNet-Asia. For years, he has been encouraging vaccine manufacturers within Asia to co-operate on selfsufficiency. Mr. Vitoon started his career with the Rhone–Poulenc Group in 1971. He has created several vaccine ventures and is also an advisor to various biotech organizations. He is a strong advocate for the local development of innovative vaccines in Thailand.

Dr. Supamit Chunsuttiwat



Thailand Ministry of Health Dr. Chunsuttiwat, is an expert in immunization and epidemiology. He has a 30-year history in the field of communicable diseases and has served as an advisor to the World Health Organization in numerous capacities. Dr. Chunsuttiwat earned his MD and MPH from Mahidol University in Bangkok and was Hubert Humphrey Fellow at Emory University and the Centers Disease Control and Prevention in Atlanta.

Michael Ward



WHO

Michael Ward is Coordinator, Regulatory System Strengthening, Essential Medicines and Health Technologies, Health Systems and Innovation Cluster, WHO Headquarters. Mike previously worked within Health Canada for close to 30 years as GMP specialist, drug evaluator and manager, international policy analyst and for the past 15 years as Manager of the International Programs Division of the Therapeutic Products Directorate. Mike has a BSc in Physiology from McGill University.



Developing Countries Vaccine Manufacturers Network Annual General Meeting 2015

Day 2, 06th October 2015	10h50	Vaccines Supply & Procurement session
Mahima Datla	Biological E	Mahima Datla directly oversees strategic operations within Biological E organization and leads the work related to public policy. She has been working with BE for the past 17 years and has served in various capacities across a diverse range of functions. Apart from Biological E, Mahima has served on the steering committee of DCVMN as well as GAVI Board, is currently a member of CII National Biotech committees and a GHIT fund board member.
Peter Khoury	Bill and Melinda Gates Foundation	Peter Khoury is a Senior Program Officer, Life Sciences Partnerships within the Global Health Office of the President, for the BMGF. His responsibilities involve working with vaccine manufacturers to explore ways of offering high quality, low cost vaccines to the world's poorest populations. Peter obtained his Ph.D. in Microbiology from Syracuse University and a MBA from Cornell University's Johnson Graduate School of Management. Peter spent 20 years in various positions of increasing responsibility with Merck and Co. and Baxter International.
Heather Deehan	UNICEF	Heather Deehan is the Chief, Vaccines in the Supply Division, UNICEF, responsible for procurement of vaccines globally. Prior to joining UNICEF, Heather was the Chief, Vaccine Preventable Diseases with the Public Health Agency of Canada, responsible for monitoring and surveillance of vaccine preventable diseases to support prevention and control of outbreaks, recommendations for the use of vaccines, and evaluation of immunization in Canada.
Melissa Malhame	Gavi	Melissa Malhame is the Head of Market Shaping at Gavi, who is responsible for working with Alliance partners and industry to ensure adequate supply of appropriate vaccines to meet demand and minimizing the costs of vaccines to Gavi and countries. Prior to Gavi, Melissa has 20 years' experience in multinational companies in leading late stage vaccine development, business, commercial development, marketing and sales, after receiving her MBA degree from the Johnson Graduate School of Management at Cornell University.



Daniel Rodriguez



PAHO

Daniel Rodríguez is Regional Advisor of the Pan American Health Organization (PAHO) Revolving Fund for Vaccine Procurement of 41 countries and territories in Latin America & the Caribbean. Daniel joined PAHO in 2010 and has more than 10 years' experience in supply chain and logistics operations in the consumer packaged goods industry in Latin America. Daniel is an Industrial Engineer, holds a master degree in business administration and in international logistics and supply chain management from the Georgia Institute of Technology.

Duncan Steele



Senior Program Officer, Enteric & Diarrheal Diseases, Bill & Melinda Gates Foundation. Duncan Steele PhD, is a microbiologist with extensive experience in virology and microbiology, especially for diarrhoeal diseases, and in clinical trials. Before starting at the foundation as a Senior


Program Officer in October 2011, and served as a scientific officer at the WHO's

Initiative for Vaccine Research.



Christopher Warburton





Christopher (Edge) Egerton-Warburton is Fund Manager, The Global Health Investment Fund and Founding Partner a founding partner of Lion's Head Global Partners, a London and Nairobi based investment banking firm that specializes in finance for emerging markets, with a focus on sustainable development. Prior to establishing Lion's Head, he spent 14 years at Goldman Sachs within the Debt Capital Markets group. He holds an MA in biochemistry from Oxford University.



Day 2, 06th October 2015

13h30

Novel Technologies

Dr. Morena Makhoana



Biovac Institute

CEO of the Biovac Institute since 2010 where he began his corporate career and now Deputy CEO of Litha Healthcare Group Limited. A Board member of Litha Healthcare Group Ltd, part of the Advisory panel at Cape Peninsula University of Technology and DCVMN Executive Committee member. Dr Makhoana holds an MBChB from the University of Cape Town.

Hyi-Jeong Ji



Green Cross Corporation Ltd. Hyi-Jeong Ji is currently the Senior Vice President of Green Cross Corporate, Ltd. in responsible for Corporate Korea. Development. After receiving her PhD in Biochemistry from Purdue University, she continuously held a research scientist position at Purdue University in the area of molecular and cell biology. Since she began her corporate career in Institute of Biotech of R&D center in LG Chemicals, she has 17 years' experience working for biopharmaceuticals and vaccine development in LG Life Sciences prior to joining Green Cross Corporate, Ltd.

Maria Bottazzi



Sabin Institute

Maria Bottazzi is Associate Dean, National School of Tropical Medicine, Baylor College of Medicine in Houston, Texas, and Professor at the Departments of Pediatrics (Tropical Medicine) and Molecular Virology and Microbiology, Integrative Molecular and Biomedical Sciences Program, and Translational Biology and Molecular Medicine Program.

Dr. Krishna Ella



Bharat

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech completed Ph.D. from University of Wisconsin-Madison. Dr. Ella is involved in shaping India's science education and policy. He is Member of Scientific Advisory Committee to the Gol; Member of the Governing Body of the Council of Scientific & Industrial Research; Chairperson of the Board of Governors of the National Institute of Technology, Warangal; Was Co-Chairman of Indo-USA High Technology Cooperation Group for 5 years on behalf of GoI; Research Council Member of Centre for Cellular & Molecular Biology.



Sue Nie Park



EuBiologics

Dr. Sue-nie Park, Vice President and Director of Research Center, EuBiologics Co. Ltd. She received MS from Seoul Nat. Univ. and Ph.D from Washington State Univ. in Microbio./ Public Health & Bacteriol. Dr. Park has worked as a researcher and developer at KRIBB (Korean Research Inst. of Biosci. & Bioeng.) for 13 years as a Chief of Virology/ Oncology Lab. She moved to KFDA to serve as a director evaluating biological products including vaccine approval for 15 years.

Jacqueline Deen



DOVE

Dr Jackie Deen presently supports the Delivering Oral Vaccines Effectively (DOVE) project based at the Johns Hopkins Bloomberg School of Public Health. She is the DSMB chair for a rotavirus vaccine trial in Niger, a member of the technical advisory Sanofi's aroup for denaue effectiveness studies in Asia and a volunteer consultant at the Vicente Sotto Memorial Medical Centre in Cebu, Philippines. She has written book chapters on cholera and malaria and has published over a hundred peer-reviewed articles.

Hun-Taek Kim Ph.D



SK

Hun-Taek Kim is currently the Vice President, Head of Bio R&D and Global Business Development at SK Chemicals Co., Ltd. After completing his BSc and MSc in Korea University in Agricultural Chemistry and Microbiology respectively, he obtained his PhD in Biotechnology from Ajou University, during which he was also implicated in Green Cross Co. and Berna Biotech; and he has been working at SK Chemicals since 2008.



Manufacturers Network		itierar meeting 2010
Day 2, 06th October 20	15 13h30	Novel Vaccines
Dr. Do Tuan Dat	VABIOTECH	President and general Director of Company for Vaccine and Biological Production No 1 (VABIOTECH), Ministry of Health in Vietnam, the leading Company for Vaccine Production in Vietnam. Since 2000 Dr. Dat was Chief of R&D Department, VABIOTECH, and was involved in the main studies for the Development of Hepatitis A Vaccine, Hib Conjugate vaccine, Vero Cellbased Rabies vaccine, A/H5N1 influenza vaccines, among others. He holds a PhD in virology from the Institution - National Institute of Hygiene and Epidemiology.
Alexander Precioso	Butantan	Alexander R Precioso is Clinical Director of Instituto Butantan, São Paulo with expertise in Clinical Trials, Epidemiology, Pediatrics and vaccine research. He has been responsible for coordinating the integration between the Project Management Office, the Technology Transfer Office, and The Innovation Technology Unit at Butantan institute since 2015. Dr Alexander R Precioso is member of the Scientific and Technical Council of Butantan Institute, and a member of The Advisory Permanent Committee on Immunization of Secretariat of Health of Sao Paulo State-Brazil.
Pham Hong Thai	BioNet- Asia	Dr. Pham Hong Thai is the CEO and co- founder of BioNet-Asia, a Thai company focus on the development and supply of vaccines. He began his career in the healthcare industry in France and moved to Chiron Biocine (now GSK) in Italy, where he held several positions in business development, strategic and international marketing. Dr. Pham graduated with a Pharm. D. from the University of Lyon in France.
Li Shi	Zerun Biotech	Li Shi is the Vice President at Walvax Biotechnology Co Ltd. And CEO and Board Director, Shanghai Zerun Biotechnology Co., Ltd. Dr. Li Shi has nearly 25 years of experience working in the US in manufacturing support management and the R&D of vaccines and biological protein products.



Luis Roberto Castelo Branco



He is the Scientific Director, Fundacao Ataulpho de Paiva. Brazilian League against Tuberculosis. Brazil. Luiz holds MD, MS, PhD.

Guoyang Liao, PhD



IMBCAMS

FAP

Head of Sabin IPV group, Director of Biologicals 5, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College. He is in charge of Sabin IPV, influenza virus vaccine, and Haemophilus b Conjugate Vaccine, including preclinical researches, registration application, potency, and clinical trials. His experience in vaccine since 1992 has given him insights in the development of new vaccines.



Manufacturers Network	Allitual Ge	merar meeting 2015
Day 2, 06th October	15h15	Executive Panel Discussions Vaccine Markets
Joshua Chu	CHAI	Joshua Chu is the Senior Regional Program Director (Southeast Asia/Pacific) at the Clinton Health Access Initiative (CHAI), where he is responsible for the development of new programs in the Southeast Asia/Pacific region, which includes Cambodia, Indonesia, Laos, Myanmar, Papua New Guinea, and Vietnam. He also concurrently holds the role of Director of Global Markets, in which he oversees CHAI's work to increase access to affordable and reliable supply of vaccines.
Melissa Malhame	Gavi Alliance	Melissa Malhame is the Head of Market Shaping at Gavi, who is responsible for working with Alliance partners and industry to ensure adequate supply of appropriate vaccines to meet demand and minimizing the costs of vaccines to Gavi and countries. Prior to Gavi, Melissa has nearly 20 years o experience in multinational companies in leading late stage vaccine development, business, commercial development, marketing and sales, after receiving her MBA degree from the Johnson Graduate School of Management at Cornell University.
Dr. Krishna Ella	Bharat Biotech International	Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech completed Ph.D. from University of Wisconsin-Madison. Dr. Ella is involved in shaping India's science education and policy. He is Member of Scientific Advisory Committee to the Gol; Member of the Governing Body of the Council of Scientific & Industrial Research; Chairperson of the Board of Governors of the National Institute of Technology, Warangal; Was Co-Chairman of Indo-USA High Technology Cooperation Group for 5 years on behalf of Gol; Research Council Member of Centre for Cellular & Molecular Biology.
Li Shi	Zerun Biotech	Li Shi is the Vice President at Walvax Biotechnology Co Ltd. And CEO and Board Director, Shanghai Zerun Biotechnology Co., Ltd. Dr. Li Shi has nearly 25 years of experience working in the US in manufacturing support management and the R&D of vaccines and biological protein products.



Manufacturers Network Fernando Lobos



Sinergium Biotechnology Fernando Lobos, Engineer and MBA, is the Business Development Director at Sinergium Biotech SA. With 20-years' experience in management, focused on new business development, engineering, start-up and operations of pharmaceutical companies. Previous experience includes positions as Operations Manager, Latin America Supply Chain Manager, Production Manager and Engineering Manager in top multinational companies starting in 1995. He obtained his degree in Engineering from ITBA, Argentina, and his MBA from IAE Argentina.

Day 2, 06th October

16h00

Executive Panel Discussions Building Trust in Vaccination

Dr. Stephen Inglis



NIBSC

Director of the National Institute for Biological Standards and Control (NIBSC), a Centre within the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Dr Inglis is a member of the MHRA Executive Management Team and serves on a number of UK advisory committees.

Amie Batson



PATH

Amie Batson, MBA, is responsible for guiding PATH's strategy, strengthening our partnerships and business relationships in the global health community, and contributing to our advocacy and policy priorities. Ms. Batson's 20-year career in global health includes positions with the World Health Organization, the World Bank, UNICEF, and most recently, the US Agency for International Development (USAID), where she served as senior deputy assistant administrator for global health.

Suresh Jadhav




Serum Institute of India

Dr. Suresh Jadhav, Executive Director of Serum Institute of India Ltd., is associated with DCVMN since 2000 and was its President from 2003 to 2008. He was member on GAVI Board & PPC. He is currently member on EVI, FastVac and HIP, besides on other Committees. He has participated in several collaborative studies for making revisions in international reference standards for WHO, NIBSC, EVI, NVI etc. and has published more than 95 technical papers in the national &



international journals.

Peter Carrasco



IAM (Sabin Institute) Peter Carrasco joined the Sabin Vaccine Institute in 2012 as Director of the International Association of Immunization Managers (IAIM) Secretariat. From 1979 to 2010, Mr. Carrasco worked with the WHO immunization program. Mr. Carrasco was stationed in Washington DC, after which he assumed the position of Policy Advisor-Vaccine Security in the Department of Immunization, Vaccines and Biologics at WHO Headquarters in Geneva, Switzerland. He received a bachelor's degree in Political Science from University of Illinois and a master's degree Public Health in Administration from Michigan State University.

Day 2, 06th October 2015

15h15

Executive Panel Discussion The Power of Multi-center Clinical Trials

Odile Leroy



European Vaccine Initiative Odile has been the Executive Director of the European Vaccine Initiative. formerly European Malaria Vaccine Initiative (EMVI) since 2006. Odile joined EMVI in 2002 as Clinical and Regulatory Director, and from 2005 to 2006, she headed the European and Developing Countries' Clinical Partnership as Executive Director. Odile is of the FP7 vaccine coordinator infrastructure project TRANSVAC, and a member of the WHO product development group for the measles aerosol project. Odile is a trained physician who has specialized in of epidemiology, areas clinical pharmacology, and vaccinology.

Alexander Precioso



Butantan

Alexander R Precioso is Clinical Director of Instituto Butantan, São Paulo with expertise in Clinical Trials, Epidemiology, Pediatrics and vaccine research. He has been responsible for coordinating the integration between the Project Management Office, the Technology Transfer Office, and The Innovation Technology Unit at Butantan institute since 2015. Dr Alexander R Precioso is member of the Scientific and Technical Council of Butantan Institute, and a member of The Advisory Permanent Committee on Immunization of Secretariat of Health of Sao Paulo State-Brazil.



David Curry



Center for Vaccine Ethics & Policy Mr. Curry is a co-founder and the Executive Director of the Center for Vaccine Ethics & Policy (CVEP), a program of NYU's Division Medical Ethics/NYU Medical School/Langone Medical Center. **CVEP** addresses and consults on global ethics and policy issues across the vaccine life cycle, with a special focus on developing country contexts and immunization in humanitarian emergencies. He is also Founding Director of the Center for Governance, Evidence, Ethics, Policy, Practice, along with other board positions.

Day 2, 06th October 2015	16h15	Executive Panel Discussion Vaccine Security
Dr. Jerome Kim	IVI	Director General International Vaccine Institute Jerome Kim, M.D. Director-General of the International Vaccine Institute (IVI), is an international expert on the evaluation and development of vaccines. He has strong scientific experience spans basic research through advanced clinical development.
Vincente Verez	Instituto Finlay de Vacunas	Vicente Verez has been the Director General of Finlay Institute since 2014. Previously he was Director General of Centro de Quimica Biomolecular, and Director of Centro de Antigenos Sinteticos. He has published numerous papers in renowned peerreviewed journals, and has been decorated with awards and honors for his devotion for science and, especially vaccines. Vicente obtained his Master's degree in Technology and chemical engineering from Instituto de Tecnologia Quimica Fina Iomonosov, and obtained his Doctor de estado from Université d'Orléans.
Heather Deehan	UNICEF	Heather Deehan is the Chief, Vaccines in the Supply Division, UNICEF, responsible for procurement of vaccines globally. Prior to joining UNICEF, Heather was the Chief, Vaccine Preventable Diseases with the Public Health Agency of Canada, responsible for monitoring and surveillance of vaccine preventable diseases to support prevention and control of outbreaks, recommendations for the use of vaccines, and evaluation of immunization programs in Canada.



Raj Mehta



Cadila Biopharmaceutical

Currently President, Cadila development responsible for commercialization of Vaccines, Biosimilars, Diagnostics and Innovation for Cadila Biotech, India. Previously he was Head of South East Asia marketing for Novartis Vaccines, including Thailand, Philippines, Vietnam, Singapore, Indonesia, Malaysia, Hong Kong, Taiwan, Macau, Bangladesh, Pakistan, Cambodia, Laos, Brunei and Myanmar. He was also responsible for development of several management and leadership training for managers of industry programs.

Dr. Morena Makhoana



Biovac Institute

CEO of the Biovac Institute since 2010 where he began his corporate career and now Deputy CEO of Litha Healthcare Group Limited. A Board member of Litha Healthcare Group Ltd, part of the Advisory panel at Cape Peninsula University of Technology and DCVMN Executive Committee member. Dr Makhoana holds an MBChB from the University of Cape Town.

Nakorn Premsri



Thai CDC/ Asean Dr.Nakorn Premsri is currently the Director of Principal Recipient Administrative Office of Department of Disease Control (PR-DDC) and has been working at the Ministry of Public Health since 1993. He worked as an epidemiologist in Sakaew Provincial Hospital, Thailand, for 5 years before moving to HIV Vaccine Trial Project (RV144-Thai Trial) in 2003. He gained experiences in the vaccine field by working in RV144 trial and became the head of vaccine R&D at National Vaccine Committee Office (NVCO).



Developing Countries Vaccine Manufacturers Network Annual General Meeting 2015

Day 3, 07th October 2015	8h00	International Cooperation For Global Access to Vaccination
Shirley Quesada	PAHO	MSc Shirley Quesada is the Revolving Fund Procurement, Unit Chief at PAHO/WHO (PAN American Health Organization/World Health Organization); she is responsible for the management of the acquisition for vaccines, immunoglobulin, syringes, and cold chain equipment. MSc Quesada has more than 20 years of experience in Public and International procurement and holds a BA in International Business Administration and a Master in Public Finance and Economics.
Debra Kristensen	PATH	Group Leader for Vaccine and Pharmaceutical Technologies at PATH, focusing on formulation, delivery devices, and supply systems and equipment. She currently chairs the Vaccine Presentation and Packaging Advisory Group, which provides a forum for public sector and vaccine industry representatives to reach consensus on specifications for vaccine presentation. Prior, Debra was the product manager for SiMED Corporation, and a chemist/toxicologist for SmithKline Laboratories. Ms. Kristensen has a biology degree from Pacific Lutheran University.
Peter Carrasco	IAM (Sabin Institute)	Peter Carrasco is Director of the International Association of Immunization Managers (IAIM) Secretariat, at the Sabin Vaccine Institute since 2012. From 1979 to 2010, Mr. Carrasco worked with the WHO immunization program, in Washington DC, after which he assumed the position of Policy Advisor-Vaccine Security in the Department of Immunization, at WHO in Geneva, Switzerland. He received a bachelor's degree in Political Science from University of Illinois and a master's degree in Public Health Administration from Michigan State University.



Day 3, 07th October 2015

13h30

Introduction to Quality by Design workshop

Dr Guenter Jagschies



GE Health Care, Sweden

Günter Jagschies is Senior Director with GE Healthcare Life Sciences with the BioProcess European HQ Division. His current role is Strategic Customer Relations, working globally with industrial R&D collaborations and as an advisor for the GE Healthcare BioProcess R&D and Business team. He holds a PhD in Biochemistry from the University of Münster, Germany.

Dr Priyabrata Pattnaik



Merck-Millipore

Worldwide Vaccine Initiative Director Merck Millipore (a division of Merck KGaA) Singapore. Dr. Priyabrata Pattnaik is Director of Worldwide Vaccine Initiative of Merck Millipore. He is the global technical/market lead for vaccine initiative supporting R&D and integrated solutions for vaccines and a thought leader on vaccine technology. He was head of Bio-manufacturing Sciences and Training Centre in Singapore and led a group of process engineers providing consulting services, educational seminars and applications support on Merck Millipore's Process Solutions, products and technologies.

Dr Mats Lundgren



GE Health Care

Scientist, R&D. Life Sciences, Healthcare, Sweden. Mats has more than 25 years of experience in the field of vaccinology. He holds a PhD in Immunology, Cell and Molecular Biology from the Karolinska Institute, and extensive postdoc training at the MRC Clinical Sciences Centre, Imperial College School of Medicine in London.

Tathagata Ray



Merck Millipore Tathagata Ray is manager of biomanufacturing sciences network, India. He has been working in technical support function for last eight years in Merck Millipore. Mr. With a strong background on development, scale up, integration, economics and troubleshooting related experience, his team offers consultancy and other technical services to Indian Biopharmaceuticals. Prior to joining Merck Millipore, he worked at Sartorius on bioreactor designing. Mr. Ray holds master degree in Biotechnology and has several publications and conference presentations.



Manufacturers Network Peder Bergvall



GE Healthcare Life Science

Bergvall, MSc, Application Scientistis Peder currently holdin a position in GE Healthcare Life Sciences R&D, Sweden. Peder has worked 15 years with development of assays for allergy diagnosis at Pharmacia Diagnostics, Uppsala. During the last 25 years, Peder held several positions within R&D at GE Healthcare, with focus on method development and applications. Since 2004 worked with development of virus purification processes and market support activities.

Michael Payne



Merck Millipore Michael Payne is Senior Consultant - Aseptic Processing at Merck Millipore Asia supporting compliance and best practices in sterile and aseptic processing. He has been in a variety of positions in Australia, Asia and the USA including ten years in Bedford USA as Manager of Worldwide Technical Training, and ten years as Asian Validation & Technical Support Manager. Michael graduated from the University of New South Wales in Sydney Australia with a degree in Chemical Engineering specializing in Bioprocess Technology.